Articles related to CANCER SCREENING

A study of 107 pregnant or postpartum persons with unusual prenatal cfDNA screening results found that specific genomic patterns—particularly the presence of copy-number gains and losses across three or more chromosomes—were associated with occult cancer in 95.9% of cases, suggesting potential new criteria for risk stratification.

Early detection remains paramount – 90% of early-stage colon cancer patients survive at least 5 years after diagnosis, emphasizing the critical importance of timely screening.

In the BLUE-C trial, Cologuard Plus demonstrated a 93.9% sensitivity for colorectal cancer detection, significantly outperforming the 67.3% sensitivity of FIT.

AI-assisted diagnosis of lung cancer showed 87% sensitivity and 87% specificity in a meta-analysis, suggesting potential for improved accuracy in interpreting chest CT scans.

In a population-based trial, MRI-targeted biopsy significantly reduced the detection of clinically insignificant prostate cancer compared to systematic biopsy, without increasing the risk of advanced cancer detection. These findings support the use of MRI-targeted biopsy as a more efficient and safer screening method.

The FDA’s new mandate requires all mammography facilities to inform women about their breast density, recognizing its significance in cancer risk and detection challenges.